We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $269M
1-Year Est. Return 103.38%
This Fund
S&P 500
This Quarter Est. Return
+22.87%
1 Year Est. Return
+103.38%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$269M
AUM Growth
+$20.3M
Cap. Flow
-$13.3M
Cap. Flow %
-4.93%
Top 10 Hldgs %
74.04%
Holding
45
New
9
Increased
7
Reduced
11
Closed
10

Top Buys

Rank Stock Value
1
VSTM icon
Verastem
VSTM
+$8.94M
2
ABVX
Abivax
ABVX
+$2.36M
3
FENC icon
Fennec Pharmaceuticals
FENC
+$2.28M
4
HELP
Cybin Inc
HELP
+$2.13M
5
NRXS icon
Neuraxis
NRXS
+$1.64M

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$6.54M
2
VRDN icon
Viridian Therapeutics
VRDN
+$4.9M
3
PCVX icon
Vaxcyte
PCVX
+$4.89M
4
CLDX icon
Celldex Therapeutics
CLDX
+$4.2M
5
DFTX
Definium Therapeutics
DFTX
+$2.36M

Sector Composition

Rank Sector Weight
1 Healthcare 98.9%
2 Miscellaneous 1.1%

No holdings matched the selected filter criteria.

1 2

Similar funds

GPFA
Game Plan Financial Advisors Westlake, Ohio $269M AUM 28.74% 1-Year Est. Return
AFO
Allie Family Office Miami, Florida $269M AUM 20.18% 1-Year Est. Return
TW
Titan Wealth St Peter Port $269M AUM
PM
Plustick Management Charlottesville, Virginia $269M AUM 340.55% 1-Year Est. Return
ZEP
Zeno Equity Partners London, United Kingdom $269M AUM 6.35% 1-Year Est. Return
LBW
Landesbank Baden-Wuerttemberg Stuttgart Baden-Wuerttemberg, Germany $269M AUM
VP
Verisail Partners Chamblee, Georgia $270M AUM 16.03% 1-Year Est. Return
5W
5T Wealth Napa, California $269M AUM 17.81% 1-Year Est. Return

Rosalind Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Rosalind Advisors held 45 positions worth $269M, up 8.2% from $249M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Rosalind Advisors withdrew a net $13.3M in Q2 2026, closing 10 positions and reducing 11 holdings. Its most notable exit was CG Oncology, an estimated $6.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, Rosalind Advisors opened a new position in Abivax worth $2.78M.

  • Rosalind Advisors's largest Q2 2026 buy was Abivax: 20,869 shares worth $2.78M.
  • Rosalind Advisors added most to Verastem in Q2 2026, an estimated $8.94M increase.
  • Rosalind Advisors's biggest Q2 2026 reduction was Vaxcyte, cutting an estimated $4.89M.
  • Rosalind Advisors fully exited CG Oncology in Q2 2026, selling an estimated $6.54M.
  • Rosalind Advisors's ten largest holdings make up 74% of its $269M portfolio in Q2 2026.
  • Rosalind Advisors opened 9 new positions and closed 10 in Q2 2026.
  • Rosalind Advisors's portfolio value rose 8.2% quarter-over-quarter to $269M.

Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.